Back
Renal transplantation (RT) is the treatment of choice for end-stage renal disease. end-stage renal disease. Patients present certain risk factors under immunosuppressive treatment (diabetes, hyper-cholesterolaemia, obesity, hyperuricaemia, hypertension). The latter remains frequent and represents a major risk factor which has a significant impact on renal graft survival of the kidney graft as well as that of the patient (pt).
This is a retrospective, observational, descriptive and analytical study. It was carried out at the Sahloul University Hospital in Sousse between 12 November 2007 and 30 October 2015.
We collected 149 pts, 143 of which were transplanted from living donors and 6 from brain-dead donors. The mean age was 35 years;The sex ratio M/F was 2.10.Chronic interstitial nephropathy was the most common nephropathy (43.6%). Prior to RT, 64.4% had hypertension, of which
51.04% were on monotherapy (29.16%). 16.1% of donors had aBMI ≥30 kg/m2.All pts had received induction immunosuppression based on boli demethyl prednisolone associated with polyclonal antibodies in 75% of cases. Wefound that 51% of patients were receiving MMF, tacrolimus and corticosteroids forcorticosteroids.Eighty-five of our patients (57%) were hypertensive after RT. Of these, 66 were hypertensive before RT and 19 developed de novo hypertension. 46,87% initially hypertensive normalized their blood pressure after RT. The significant risk factors were: age, male sex, previous history of as well as the choice of anti-calcineurin maintenance therapy.
Hypertension is a frequent complication after RT. There is no reduction in its incidence compared with dialysis. compared with dialysis. Hypertension after RT is multi-factorial. The immunosuppressive treatment based on anti-calcineurin is the main cause of hypertension
cause of hypertension after TR.